TITLE

VIRACEPT COMBINATIONS STUDIES

PUB. DATE
June 1998
SOURCE
AIDS Patient Care & STDs;Jun98, Vol. 12 Issue 6, p495
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Presents information on the fifth Conference on Retroviruses and Opportunistic Infections in Chicago in 1998. Summarization of the results from clinical trials of the drug Viracept; Use of the drug with other protease inhibitors and anti-human immunodeficiency virus (HIV) drugs; Evaluation of Viracept in combination with Fortovase; Methodology used in the trials; Conclusions of the trials.
ACCESSION #
805524

 

Related Articles

  • Treat HIv-1 Infected with at Least Two Antiretrovirals.  // Kidney;Sep/Oct99, Vol. 8 Issue 5, p203 

    Discusses an abstract of the article, entitled `Effect of hemodialysis and antiretroviral therapy on plasma viral load in HIV-1 infected hemodialysis patients,' by T.S. Ahuja, N. Niaz. A. Velasco and others.

  • A Cohort Study of Nevirapine Tolerance in Clinical Practice: French Aquitaine Cohort, 1997--1999. Bonnet, F.; Lawson-Ayayi, S.; Thiébaut, R.; Ramanampamonjy, R.; Lacoste, D.; Bernard, N.; Malvy, D.; Bonarek, M.; Djossou, F.; Beylot, J.; Dabis, F.; Morlat, P. // Clinical Infectious Diseases;11/15/2002, Vol. 35 Issue 10, p1231 

    We performed a retrospective study to evaluate, under routine circumstances, the tolerance and immunovirological changes associated with antiretroviral regimens that contain nevirapine in 137 patients (88% were antiretroviral experienced). During a mean follow-up of 11 months, 33% of patients...

  • Stavudine Once Daily. Cheer, S.M.; Goa, K.L. // Drugs;2002, Vol. 62 Issue 18, p2667 

    â–´ Stavudine administered once daily is a nucleoside analogue reverse transcriptase inhibitor. â–´ The efficacy (reduction in viral load and increase in CD4+ lymphocyte counts from baseline) of stavudine once daily-containing triple therapy was similar to that of stavudine immediate...

  • Failure of a prospective trial to detect cytomegalovirus retinitis after initiation of highly... Uphold, Constance R.; Smith, Fran // AIDS Patient Care & STDs;Dec98, Vol. 12 Issue 12, p907 

    Determines the incidence of cytomegalovirus (CMV) retinis prior to and after initiation with highly active antiretroviral therapy (HAART). Decrease in viral loads and increase in CD4+ T-cell counts after starting HAART; Non-occurrence of CMV retinis among patients receiving HAART; Development...

  • SELF-REPORTED ADHERENCE NOT RELIABLE.  // AIDS Patient Care & STDs;Jan1999, Vol. 13 Issue 1, p59 

    Reports that self-reporting of adherence to various anti-retroviral therapies is not a reliable method when used alone. Electronic monitoring of adherence.

  • Adherence Assessment to Highly Active Antiretroviral Therapy. Tsasis, Peter // AIDS Patient Care & STDs;Mar2001, Vol. 15 Issue 3, p109 

    Adherence to highly active antiretroviral therapy (HAART) is the outcome of a dynamic process of clinical and behavioral interactions. This article reviews factors influencing this process and provides suggestions to enhance adherence to HAART. Interventions to improve adherence to HAART should...

  • T-20 SHOWS PROMISE.  // AIDS Patient Care & STDs;Mar1999, Vol. 13 Issue 3, p200 

    Reports on the results of the first multidose human trial of the antiretroviral T-20. Decrease in patients' viral load; Results of similar trials using triple-drug HAART and four-drug HAART.

  • Switching Effective Antiretroviral Therapy: A Review. Drechsler, Henning; Powderly, William G. // Clinical Infectious Diseases;11/15/2002, Vol. 35 Issue 10, p1219 

    One approach to target the long-term metabolic toxicity and disfiguring body-shape changes associated with antiretroviral therapy is to switch one component of a regimen to an alternative drug, usually from a different class of antiretrovirals. Most commonly, substitutions have involved protease...

  • Predicting the unpredictable: Transmission of drug-resistant HIV. Blower, S.M.; Aschenbach, A.N.; Gershengorn, H.B.; Kahn, J.O. // Nature Medicine;Sep2001, Vol. 7 Issue 9, p1016 

    Traces the evolution of the epidemic of antiretroviral drug resistant HIV in San Francisco, California, as of September 2001. Prevalence of the epidemic in the period between 1996 to 2001; Key factors in the transmission of antiretroviral therapy resistance; Predictions for the period from 2001...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics